Мақола

Antimicrobial resistance in Shigella species: Our five years (2015–2019) experience in a tertiary care center in north India

Neelam TanejaDepartment of Medical Microbiology, Postgraduate Institute of Medical Education and Research, 160012, India. Electronic address: [email protected]Jutang Babat Ain TiewsohDepartment of Medical Microbiology, Postgraduate Institute of Medical Education and Research, 160012, India. Electronic address: [email protected]Swati GuptaDepartment of Medical Microbiology, Postgraduate Institute of Medical Education and Research, 160012, India. Electronic address: [email protected]Balvinder MohanDepartment of Medical Microbiology, Postgraduate Institute of Medical Education and Research, 160012, India. Electronic address: [email protected]Ritu VermaDepartment of Medical Microbiology, Postgraduate Institute of Medical Education and Research, 160012, India. Electronic address: [email protected]Pinky ShankarDepartment of Medical Microbiology, Postgraduate Institute of Medical Education and Research, 160012, India. Electronic address: [email protected]Chandradeo NarayanDepartment of Medical Microbiology, Postgraduate Institute of Medical Education and Research, 160012, India. Electronic address: [email protected]Vivek Kumar YadavDepartment of Medical Microbiology, Postgraduate Institute of Medical Education and Research, 160012, India. Electronic address: [email protected]Muralidharan JayashreeDivision of Pediatric Emergency and Intensive Care, Department of Pediatrics, Advanced Pediatrics Centre, Postgraduate Institute of Medical Education and Research, 160012, India. Electronic address: [email protected]Surjit SinghDivision of Pediatric Allergy & Immunology, Head of Department, Department of Pediatrics, Advanced Pediatrics Centre, Postgraduate Institute of Medical Education and Research, 160012, India. Electronic address: [email protected]

Indian Journal of Medical Microbiologyjournal2021en

ABI

Аннотация

PURPOSE: Shigella is the second leading cause of diarrhoeal mortality especially in children <5 years of age in African and Asian countries. Rapid changes are occurring in the epidemiology of shigellosis and Shigella are increasingly becoming highly drug resistant. To determine the serogroup distribution and antimicrobial resistance of Shigella isolated at our tertiary care centre in North India. METHODS: December 2019 were retrieved from records and analyzed by WHONET 2019 software. RESULTS: Shigella species was isolated in 1.31% (n = 137) of a total of 10,456 stool samples. Males predominated (n = 82; 59.8%) and majority of cases were admitted (n = 94; 68.6%). Children ≤5 years of age (n = 47; 34.3%) were the most commonly affected. Adults in the 21-40 age group contributed 27% of cases (n = 37). Overall, Shigella flexneri (n = 87; 63.5%) was the most common serogroup followed by non-agglutinable Shigella (n = 28; 20.4%) while Shigella sonnei (n = 12, 8.8%) and Shigella boydii (n = 9, 6.6%) fluctuated over the years. Shigella dysenteriae reappeared in 2019 after a hiatus of ten years. Overall, 45.3% (n = 62) of isolates were multidrug resistant to CLSI recommended drugs and high resistance was noted for ampicillin/amoxicillin (68.1%), cotrimoxazole (75.8%) ciprofloxacin (61.5%) and ceftriaxone/cefotaxime (45.2%). CONCLUSIONS: Shigella have become highly drug resistant to fluoroquinolones and cephalosporins. Community based studies are required to truly assess the burden of AMR in India.

Ҳали таржима қилинмаган

Мавзулар

Escherichia coli research studies Viral gastroenteritis research and epidemiology Amoebic Infections and Treatments

Идентификаторлар

DOI: 10.1016/j.ijmmb.2021.06.002

Иқтибослар ва манбалар

0 та иқтибос28 та фойдаланилган манба

Кўрсаткичлар — AkademScholar